Updates in HER2 (ERBB2)-Mutant Metastatic Non-small Cell Lung Cancer Treatment: Small Population, Big Unmet Need
Year: 2025
Type: article
Abstract: Treatment: Small Population, Big Unmet NeedThe FDA has now approved zongertinib, a kinase inhibitor indicated for the treatment of adult patients with unresectable or metastatic non-squamous NSCLC whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy.*For U.S. Healthcare Professionals, please see full Prescribing Information.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Funder: Boehringer Ingelheim
OpenAlex ID: W4414606704